Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential
PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.
How this was made
The 30-second read
Why it matters
Enrollment completion and FDA IDE approval reduce execution uncertainty and strengthen the probability-weighted path to future efficacy readouts, which can drive analyst and investor re-rating.
Market read
Traders may adjust expectations for aquablation’s competitive and commercial outlook based on new trial milestones and the initiation narrative.
What to watch
Trial timelines (spring 2027 presentation; 10-year follow-up) and the risk that Grade Group 1–2 outcomes or quality-of-life endpoints fail to meet expectations could cap the multiple expansion narrative.
Background
PROCEPT is advancing aquablation in prostate cancer via WATER IV RP (vs radical prostatectomy) and WATER IV AS (vs active surveillance).
Ticker impact
PROCEPT BioRobotics disclosed WATER IV RP enrollment completion and received FDA IDE approval for WATER IV AS, expanding its aquablation trial pipeline.
Bias toward upside/volatility as traders price the next 12 months toward spring 2027 AUA presentation and ongoing trial execution.
The article’s newest facts are trial enrollment completion and FDA IDE approval, which are actionable catalysts; however, it also relies on analyst initiation rather than new trial results.
Market effects
Supports sentiment for urology/robotics-adjacent medtech platforms where aquablation trial progress can shift competitive positioning.
Primarily US-focused biotech/medtech sentiment via FDA IDE and US clinical program milestones.
WATER IV AS enrolls globally, which can broaden investor perception of international adoption potential.
Counterpoint
Milestones are execution/approval steps, not efficacy results; upside may be over-discounted until primary endpoints are actually reported.
Key entities
- companyPROCEPT BioRobotics Corporation
NASDAQ-listed company advancing aquablation through WATER IV prostate cancer studies.
- analyst_firmEvercore ISI
Initiated coverage with an Outperform rating and a $30 price target, citing aquablation growth potential.
- regulatorFDA
Approved an Investigational Device Exemption for the WATER IV AS protocol.
